$Intercept Pharmaceuticals, Inc. (ICPT)$  OCA is the FASTEST NASH candidate with phase 3 interim results to be released in 1H 2009. It remains the ONLY investigational therapy to have shown efficacy across all the key liver histologic features that inform the two currently approvable endpoints: first and foremost, fibrosis improvement, which has been shown to predict clinical outcomes; and second, NASH resolution. A therapy that can provide both of these attributes will be highly desirable to physicians treating patients with NASH.